- ImmunoGen (IMGN -1.2%) gives back yesterday's post-session gains and more after its FQ4 beat on a per share basis, reporting a narrower loss than the Street.
- Kadcyla sales off to a strong start in the U.S. for its first indication, with additional approvals expected.
- The company boosts guidance going forward, now expecting FY14 revenues of $66M - $70M, above the Street view of $49.9M.
Immunogen gives back early gains from an upbeat FQ4 report
Check out Seeking Alpha’s new Earnings Center »
From other sites
at CNBC.com (Dec 19, 2014)
at CNBC.com (Dec 2, 2014)
at CNBC.com (Sep 8, 2014)
at CNBC.com (Aug 14, 2014)
at CNBC.com (Jun 25, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs